左卡尼汀联合前列地尔治疗糖尿病肾病的临床观察  

Clinical Observation of L-Carnitine and Alprostadil in the Treatment of Diabetic Nephropathy

作　　者：张峰明 Fengming Zhang(Beijing Lianke TCM Nephrology Hospital,Beijing,100041,China)

机构地区：[1]北京联科中医肾病医院,中国北京100041

出　　处：《亚洲临床医学杂志》2019年第5期39-41,共3页Asian Journal of Clinical Medicine

摘　　要：目的:研究糖尿病肾病采用左卡尼汀联合前列地尔治疗的效果。方法:研究时段是2017.4-2019.3,研究对象我院接收的66例糖尿病肾病患者,采纳随机数字表法分为观察组(左卡尼汀联合前列地尔)与对照组(前列地尔)各33例,比较两组观察指标、肾功能、临床疗效及不良反应。结果:两组治疗前CysC与RBP指标无统计学意义,P>0.05;治疗后与对照组比较,观察组CysC与RBP指标低;BUN、SCr及β2-MG指标低;有效率高且不良反应发生率低,P<0.05。结论:左卡尼汀联合前列地尔治疗糖尿病肾病能提高整体疗效。Objective:To study the effect of L-carnitine combined with alprostadil on diabetic nephropathy.Methods:The study period was 2017.4-2019.3.The study subjects were 66 patients with diabetic nephropathy received by our hospital.The random number table method was used to divide the observation group(levonidine and alprostadil)and the control group(Alprostadil)into 33 cases each.,Compare the two groups of observation indicators,renal function,clinical efficacy and adverse reactions.Results:CysC and RBP indicators were not statistically significant before treatment in the two groups,P>0.05;compared with the control group after treatment,CysC and RBP indicators in the observation group were low;BUN,SCr,andβ2-MG indicators were low;high efficiency and adverse reactions The incidence is low,P<0.05.Conclusion:L-carnitine combined with alprostadil can improve the overall efficacy of diabetic nephropathy.

关 键 词：糖尿病肾病 左卡尼汀 前列地尔 肾功能 

分 类 号：R58[医药卫生—内分泌]